Showing 5141-5150 of 9940 results for "".
- ALASTIN Adds to Board of Directorshttps://practicaldermatology.com/news/alastin-adds-to-board-of-directors/2457837/Ann Rhoads and Elisabeth Sandoval are now members of ALASTIN Skincare, Inc’s Board of Directors. Ms. Rhoads is a healthcare finance executive with more than 25 years of experience which includes roles as Chief Financial Officer of
- Colorescience Adds to Board of Directorshttps://practicaldermatology.com/news/colorescience-adds-to-board-of-directors/2457838/David Olsen and Ty Stiklorius are joining Colorescience’s Board of Directors. David Olsen is the Chief Executive Officer (CEO) of Cos Bar. Since joining Cos Bar in February 2016, he has worked to grow the company while
- Differin Launches Retinoid Education Weekhttps://practicaldermatology.com/news/differin-launches-retinoid-education-week/2457848/Differin® has launched Retinoid Education Week to educate the more than 50 million Americans with acne about how retinoids can be used to treat their condition. Part of Nestlé Skin Health’s acne franchise, Differin is new to the over-the-counter acne category. However, retinoids
- Dermira: Two Phase 3 Trials Evaluating Olumacostat Glasaretil in Patients with Acne Vulgaris Did Not Meet Co-Primary Endpointshttps://practicaldermatology.com/news/dermira-two-phase-3-trials-evaluating-olumacostat-glasaretil-in-patients-with-acne-vulgaris-did-not-meet-co-primary-endpoints/2457852/Dermira, Inc.'s investigational treatment olumacostat glasaretil (formerly DRM01) did not meet the co-primary endpoints in its two Phase 3 pivotal trials (CLAREOS-1 and CLAREOS-2) in patients ages nine years and older with moderate-to-severe acne vulgaris. “We are surprised and
- Dr. Jacob Chacko Joins Bonti's Board of Directorshttps://practicaldermatology.com/news/dr-jacob-chacko-joins-bontis-board-of-directors/2457893/Jacob Chacko, MD has joined Bonti’s Board of Directors. Dr. Chacko has served as the Chief Financial Officer of Ignyta, Inc. since May 2014. At Ignyta, he leads multiple functions, including Finance, Accounting, Investor Relations, Communications
- Abeona Receives FDA Regenerative Medicine Advanced Therapy Designation for EB-101 Gene Therapy in EBhttps://practicaldermatology.com/news/abeona-receives-fda-regenerative-medicine-advanced-therapy-designation-for-eb-101-gene-therapy-in-eb/2457908/The US Food and Drug Administration (FDA) granted the Regenerative Medicine Advanced Therapy (RMAT) designation to EB-101, Abeona Therapeutics Inc.’s gene-corrected autologous cell therapy product for patients with recessive dystrophic epidermolysis bullosa (RDEB). “EB-101 is
- Intraderm Changes Alevicyn Product Name to Levicynhttps://practicaldermatology.com/news/intraderm-changes-alevicyn-product-name-to-levicyn/2457910/Intraderm's Alevicyn is getting a new name—Levicyn. The Gel formulation is now Levicyn Antipruritic Gel, the Spray Gel is now Levicyn Antipruritic SG, and the Dermal Spray is now Levicyn Antimicrobial Dermal Spray. The company notes that physicians can still write for Alevicyn d
- Meet JAAD's New Editor Dirk M. Elston, MDhttps://practicaldermatology.com/news/meet-jaads-new-editor-dirk-m-elston-md/2457918/Charleston, SC-based dermatologist Dirk M. Elston, MD, FAAD, is the next editor of the Journal of the American Academy of Dermatology. Dr. Elston, the journal’s current deputy editor, will step into his new role in July 2018, succeeding de
- FDA Grants AbbVie's Upadacitinib Breakthrough Therapy Designation for Atopic Dermatitishttps://practicaldermatology.com/news/fda-grants-abbvies-upadacitinib-breakthrough-therapy-designation-for-atopic-dermatitis/2457932/The FDA granted Breakthrough Therapy Designation for AbbVie's investigational, once-daily oral JAK1-selective inhibitor upadacitinib (ABT-494) in adult patients with moderate to severe atopic dermatitis who are candidates for systemic therapy. This Breakthrough Therapy Designation is supporte
- FDA Approves BMS's Opdivo as Adjuvant Therapy in Patients with Completely Resected Melanoma with Lymph Node Involvement or Metastatic Diseasehttps://practicaldermatology.com/news/fda-approves-bmss-opdivo-as-adjuvant-therapy-in-patients-with-completely-resected-melanoma-with-lymph-node-involvement-or-metastatic-disease/2457941/The FDA has approved Bristol-Myers Squibb Company's Opdivo (nivolumab) injection for intravenous use for the adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection. The purpose of adjuvant therapy is to reduce t